Podcasts about cardiol

Our initial review of the PLATO trial, published in April 2024, was based on the data available to us at that time. We have since became aware of new information that reduces our confidence in the PLATO results. This new information has major implications for clinical practice. Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.Despite representing only 6.9% of the total P2Y12 inhibitor prescriptions among Medicare beneficiaries in 2020, Ticagrelor accounted for nearly two-thirds of total Medicare spending on these drugs in the same year. We summarize important points below but you can refer to this investigation at BMJ for more details.1. Unexplained Regional Variation: In our original review, we highlighted the treatment effect interaction based on region of enrollment, where ticagrelor was less effective compared to clopidogrel for patients enrolled in North America. It appeared to be a strong signal and was associated with a p-value for the interaction of 0.05. However, we were cautious in our interpretation since overall, patients enrolled in North America represented a relatively small fraction of total patients and we could not think of a reasonable explanation.Information in the BMJ investigation now sheds new light on these findings. In our review, we only presented data contained in the supplement accompanying the PLATO trial manuscript, which categorized patients based on region of enrollment but did not provide country specific information. The BMJ report notes that in a separate subgroup analysis, based on country of randomization, the primary outcome was numerically higher with ticagrelor in the United States (12.6% vs 10.1%, HR: 1.27, 95% CI: 0.92 – 1.75). This subgroup represented 7.6% of the total trial participants. Overall, 9.7% of trial participants were enrolled from North America. This means the US data drove the findings from the North American subgroup.The explanation provided by AstraZeneca (the manufacturer of ticagrelor) to explain the observed treatment effect heterogeneity was that aspirin dosing in the United States was higher than in other countries. It even led the FDA to issue a black box warning to avoid an aspirin maintenance dose of >100 mg in patients taking ticagrelor. An extensive statistical analysis of the regional variation in PLATO yielded four interesting points. First what was the prior likelihood of observing a ticagrelor vs clopidogrel HR of > 1.25 in the US, when the overall HR was actually equal to 0.84? That probability is ≤ 0.01. This alone suggests more than chance. Second point: a strong US/nonUS interaction was noted for each of the 3 components of the primary endpoint—CV death, MI, stroke. Third: they found a very strong interaction between treatment and median aspirin dose, and, importantly, the aspirin interaction effect was similar in US and nonUS settings. Fourth, an analysis of contract research organization (CRO) vs sponsor monitoring of the site accounted for 61% of the treatment-by- region interaction. The authors downplayed this finding because of the four countries monitored by a CRO (Israel, US, Georgia and Russia), the US made up the majority and thus is confounded by the aspirin interaction. Noteworthy was a lack of direct analysis of CRO vs sponsor test for interaction. One problem though: the BMJ investigation found that the lead author, Kevin Carroll was the head statistician at AstraZeneca and had worked at the company for 20 years. Carroll presented the PLATO results at the FDA advisory meeting. The paper lists Carroll as having no conflicts. Carroll told the BMJ that he had disposed of all conflicts of interest before submitting that analysis. But, in our opinion, the aspirin explanation does not pass muster because of biologic implausibility. See next section: How would a higher dose of aspirin reduce the efficacy of ticagrelor?The primary composite endpoint was vascular death, MI or stroke. If the higher aspirin dose impacted this, we would hypothesize that it caused more major bleeding in the ticagrelor group with some events resulting in vascular death, type 2 MI and hemorrhagic stroke, driving the treatment effect in favor of clopidogrel. But there is no evidence of this.The figure below is from the original subgroup plots provided in the PLATO supplement. The difference in the treatment effect for the primary endpoint for North American patients is striking but there is no difference for major bleeding.In our opinion and the opinion of others, the role of supervision of the centers could be important. Most centers were monitored by the sponsor. Four countries (Israel, US, Georgia and Russia) were monitored by a contract research organization. All four of these countries had numerically higher rates of the primary outcome in the ticagrelor group. This has major implications and we do not take them lightly. Essentially, it suggests malfeasance on the part of the sponsor. So is there anything else to support such a claim? Well, yes. 2. Concerns about event adjudication. Based on a report from Victor Serebruany, an adjunct faculty member at Johns Hopkins University, and the BMJ investigation, FDA records indicated that site reports documented 504 myocardial infarctions in patients who received ticagrelor compared to 548 in patients who received clopidogrel. However, after adjudication, the count increased only for the clopidogrel group, reaching 593. There was also some imbalance among groups in adjudicating death. These imbalances raise concerns about potential unblinding and result tampering. We read many of the authors' replies and we did not find a clear explanation of why all readjudicated extra MIs were in the clopidogrel group (45 clopidogrel; ticagrelor 0). 3. There were also concerns about the accuracy of death records as sites death records did not always match the FDA records.We cite from the BMJ: The BMJ's analysis also found omissions in PLATO's landmark publication. The paper, published in NEJM and reported as an intent-to-treat analysis, reports 905 total deaths from any cause among all randomized patients. An internal company report states, however, that 983 patients had died at this point. While 33 deaths occurred after the follow-up period, the NEJM tally still leaves out 45 deaths “discovered after withdrawal of consent.” The BMJ obtained some records for patients whose deaths were not reported in NEJM (see table 1) and asked the journal for a response.NEJM editor in chief Eric Rubin told The BMJ that “for older manuscripts, correction is not necessarily appropriate unless there would be an effect on clinical practice,” concluding that “it does not appear that correcting this 15-year-old article is going to have any impact.”It is noteworthy that the United States Department of Justice launched a formal investigation into the PLATO trial in 2013; however, the probe was closed in 2014. The BMJ column cited a spokesperson for the US attorney's office who said…”we determined that the allegations lacked sufficient merit such that it was not in the best interests of the US to intervene in the suit.” 4. Mortality reduction in PLATO defies explanation: Shortly after PLATO was published, Drs. Victor Serebruany and Dan Atar wrote an editorial in the European Heart Journal titled: The PLATO trial: do you believe in magic? They noted that the overall HR for all-cause death ticagrelor vs clopidogrel was 0.78 (95% CI: 0.69 - 0.89; p< 0.001). There were 107 more lives saved with ticagrelor vs clopidogrel. To explain the surprise of this massive effect size, they compared it to the COMMIT trial of clopidogrel vs placebo in patients with acute MI. In COMMIT, 119 lives were saved with clopidogrel (vs placebo), but COMMIT had three-fold more patients than PLATO—and the gain was vs placebo. They tempt the reader to ask: how could ticagrelor fare that well against a drug that crushed placebo? We note two other reasons to be concerned about the outsized mortality reduction in PLATO. One is plausibility. The all-cause mortality benefit exceeded the reduction in MI, CV death or stroke. Given the numerically higher rate of bleeding, how else does ticagrelor reduce death vs clopidogrel? The second reason is the lack of such a signal in Phase 2 studies, such as this one. 5. PLATO results are on outlier: Multiple observational studies have failed to replicate the benefits of ticagrelor observed in the PLATO trial. While observational studies are inherently limited by confounding factors and are inferior to randomized trials, their findings warrant a re-evaluation of ticagrelor's benefits. Furthermore, two randomized trials—one conducted predominantly in Japanese patients and another in South Korea—did not demonstrate the superiority of ticagrelor, instead showing higher bleeding rates and a numerical increase in ischemic events.Ticagrelor also significantly underperformed against another new antiplatelet drug, prasugrel. In the non-industry-funded ISAR-REACT 5 trial, which enrolled patients with acute coronary syndrome, the primary event of death, MI, or stroke was 36% higher in the ticagrelor arm (9.3% vs 6.9%, HR 1.36, 95% CI: 1.09 - 1.70). Major bleeding was also numerically higher in the ticagrelor arm. 6. PLATO authors have responded to these arguments.We provide links to four of the authors responses. * Thrombosis and Hemostasis https://www.wellesu.com/10.1160/TH11-03-0162* Stroke https://www.ahajournals.org/doi/10.1161/strokeaha.111.000514* Inter J of Cardiol https://doi.org/10.1016/j.ijcard.2014.06.029* Circulation https://doi.org/10.1161/CIRCULATIONAHA.111.047498Conclusion These are vitally important revelations regarding PLATO and ticagrelor. The FDA advisory committee recommended that FDA require a confirmatory trial. This was not done. As such, ticagrelor gained serious market share in the non-clopidogrel antiplatelet market for more than a decade. Yet no other compelling evidence for its benefit over clopidogrel has come to light. It clearly underperformed vs prasugrel. These old and new revelations have changed our positive view of ticagrelor. We no longer have confidence in this drug. We strongly agree with the recommendation for another properly controlled trial. We also believe this highlights the benefits of having either two regulatory trials or a single regulatory trial combined with a mandated post-approval trial. These revelations also emphasize the benefits of robust critical appraisal and skeptical but not cynical approaches to surprising evidence. Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Pruebas Cardiológicas No Invasivas. - Dra. Wanda Peña, Hospiten.

For the past 60 years the medical community has obsessively focused on lowering LDL-cholesterol levels… Research shows these five preventable health conditions make LDL-Cholesterol more likely to cause artery plaque build-up, even if your LDL-Cholesterol levels are low. Sponsored: Crush your Workouts and stay hydrated this summer with the Electrolyte + Creatine Combo by MYOXCIENCE: https://bit.ly/electrolyte-stix *Save with code podcast at checkout Link to Video and Show Notes: https://bit.ly/3WfpI5R Research Mentioned: Zanoni, P., Velagapudi, S., Yalcinkaya, M., Rohrer, L. & Eckardstein, A. von. Endocytosis of lipoproteins. Atherosclerosis 275, 273–295 (2018). Ference, B. A., Braunwald, E. & Catapano, A. L. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat. Rev. Cardiol. 1–16 (2024) doi:10.1038/s41569-024-01039-5. Time Stamps: 00:45 LDL's link with atherosclerosis is nuanced.  02:30 Initial damage to the arterial wall makes LDL levels problematic. 03:45 Increases risk of arterial wall damage: elevated blood pressure, insulin resistance/diabetes, smoking/vaping, obesity, elevated blood viscosity, consuming oxidizableoils. 08:40 High LDL and high triglycerides suggest insulin resistance and increased cardiovascular risk. 09:50 Start with diet and exercise together. 11:20 Statins have concerning side effects. 13:15 Plaque formation begins early in life. 13:50 High LDL is found in centenarians. 14:44 Centenarians are metabolically healthy. 15:40 Your liver makes LDL cholesterol. 16:10 Every cell in your body requires cholesterol. 18:00  Diets high in seed oils make your LDL more likely to be oxidized. 20:55 30-50% of people who have heart attacks have optimal serum cholesterol.

Joanne, Bernardo Siqueira e Guilherme Moura discutem sobre os principais pontos no diagnóstico e tratamento das valvopatias aorticas. Referência: 1.Tarasoutchi, F., Montera, M. W., Ramos, A. I. O., Sampaio, R. O., Rosa, V. E. E., Accorsi, T. A. D., Santis, A. , Fernandes, J. R. C., Pires, L. J. T., Spina, G. S., Vieira, M. L. C., Lavitola, P. L., Ávila, W. S., Paixão, M. R., Bignoto, T., Togna, D. J. D., Mesquita, E. T., Esteves, W. A. M., Atik, F., Colafranceschi, A. S., Moises, V. A., Kiyose, A. T., Pomerantzeff, P. M. A., Lemos, P. A., Brito Junior, F. S. , Weksler, C., Brandão, C. M. A., Poffo, R., Simões, R., Rassi, S., Leães, P. E., Mourilhe-Rocha, R., Pena, J. L. B., Jatene, F. B., Barbosa, M. M., Abizaid, A., Ribeiro, H. B., Bacal, F., Rochitte, C. E., Fonseca, J. H. A. P. , Ghorayeb, S. K. N., Lopes, M. A. C. Q., Spina, S. V., Pignatelli, R. H., & Saraiva, J. F. K. (2020). Atualização das Diretrizes Brasileiras de Valvopatias – 2020. Arq. Bras. Cardiol., 115(4), 720-775.

Cardiol Therapeutics CEO David Elsley joined Steve Darling from Proactive to share some significant news: the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the company's lead small molecule drug candidate aimed at treating pericarditis, including recurrent pericarditis. This designation is a major validation of CardiolRx's potential in addressing a debilitating heart condition. Elsley explained that recurrent pericarditis is a serious heart disease characterized by symptoms that significantly impact patients' quality of life and physical activity. The FDA's decision to grant ODD underscores the potential of CardiolRx to improve the lives of individuals suffering from this condition. MAvERIC-Pilot is a Phase II open-label pilot study investigating the tolerance, safety, and effect of CardiolRx™ administered to patients with recurrent pericarditis. In addition to standard safety assessments, MAvERIC-Pilot is designed to evaluate improvement in objective measures of this rare disease. Orphan Drug Designation is granted by the FDA to drugs or biological products intended to prevent, diagnose, or treat rare diseases or conditions affecting fewer than 200,000 people in the United States. This designation offers several benefits to sponsors, including potential seven-year marketing exclusivity, exemptions from certain FDA fees, and tax credits for qualified clinical trials. Additionally, products with ODD may qualify for accelerated regulatory review through Fast Track, Breakthrough Therapy, or Priority Review designations. This milestone represents a significant advancement for Cardiol Therapeutics and its efforts to develop innovative therapies for cardiovascular diseases. With CardiolRx currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis, the ODD from the FDA further strengthens the company's position in advancing treatments for these conditions #proactiveinvestors #cardioltherapeuticsinc #nasdaq #crdl #tsx #crdl #PericarditisTreatment, #OrphanDrugDesignation, #HeartHealth, #MedicalInnovation, #RareDisease, #HealthcareNews, #ClinicalTrials, #FDAApproval, #Biopharmaceutical, #InflammationTreatment, #MedicalResearch, #HealthTech, #PatientCare, #MedicalAdvancements, #HeartDiseaseAwareness, #PublicHealth, #HealthcareIndustry, #Cardiology, #MedicalBreakthroughs, #DrugDevelopment, #HeartMedicine, #HealthcareUpdates, #MedicalScience, #HealthcareTechnology #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

While high levels of cholesterol are often associated with an increased risk of cardiovascular disease, the paradox arises when studies reveal unexpected relationships between low cholesterol levels and certain health issues. Support your Workout Sessions and Healthy Hydration with this Creatine Electrolyte Combo by MYOXCIENCE: bit.ly/electrolyte-stix Save 12% with code podcast at checkout References:  Wang, S.-S. et al. Cholesterol paradox in the community-living old adults: is higher better? J. Geriatr. Cardiol. 20, 837–844 (2023).   Murata, S. et al. Blood biomarker profiles and exceptional longevity: comparison of centenarians and non-centenarians in a 35-year follow-up of the Swedish AMORIS cohort. GeroScience 1–10 (2023) doi:10.1007/s11357-023-00936-w. Time Stamps: 00:00 High cholesterol, as you age, is protective. 01:10 Higher HDL and higher total cholesterol is associated with greater longevity and reduction in death from cardiovascular disease. 02:00 Middle aged men have a risk from high LDL and high total cholesterol. 02:25 Low Cholesterol is associated with mortality from stroke, heart disease and cancer. 05:40 Your LDL goes up as you become more metabolically healthy. 05:50 Triglycerides enrich cholesterol particles in the insulin resistant 06:15 Test your ApoB to A1 ratio. HDL and triglycerides should be close to 1:1. 07:00 Low cholesterol is a risk factor for poor prognosis for cancer.

Não tenha dor no peito durante o plantão! No quarto episódio da nova temporada, continuamos a discussão do episódio 3, sobre síndrome coronariana aguda. Neste episódio, discutimos sobre estratificação de risco e manejo terapêutico. Lojinha da Amazon (Livros e Materiais recomendados)⁠: Sigam e acompanhem a gente, nas redes: Insta: @medicinarretada Tiktok: @medicinarretada Youtube: @medarretada Site: ⁠⁠⁠⁠⁠⁠https://medicinarretada.com.br/⁠⁠⁠⁠⁠⁠ E-mail: ⁠⁠⁠⁠⁠⁠suporte@medicinarretada.com.br⁠⁠⁠⁠⁠⁠ Um "xêro" e até a próxima!

Não tenha dor no peito durante o plantão. No terceiro episódio da nova temporada, apresentamos um caso clínico de síndrome coronariana aguda (infarto agudo do miocárdio e angina instável) e discutimos sobre definições, classificação fisiopatológica, diagnósticos diferenciais, abordagem inicial e estratificação de risco. Lojinha da Amazon (Livros e Materiais recomendados)⁠: Sigam e acompanhem a gente, nas redes: Insta: @medicinarretada Tiktok: @medicinarretada Youtube: @medarretada Site: ⁠⁠⁠⁠⁠https://medicinarretada.com.br/⁠⁠⁠⁠⁠ E-mail: ⁠⁠⁠⁠⁠suporte@medicinarretada.com.br⁠⁠⁠⁠⁠ Um "xêro" e até a próxima!

Seis asociaciones referentes en cardiología  manifestaron su preocupación ante la escasez de suministros indispensables, que afecta tanto las intervenciones programadas como las urgencias.

Joanne e Fred discutem sobre o manejo de medicações no perioperatório, com foco em anti-hipertensivos e antidiabéticos - quando suspender e quando manter? Referências: 1. ESC Scientific Document Group , 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC), European Heart Journal, Volume 43, Issue 39, 14 October 2022, Pages 3826–3924. 2. Gualandro DM, Yu PC, Caramelli B, Marques AC, Calderaro D, Fornari LS, Pinho C, et al. 3ª Diretriz de Avaliação Cardiovascular Perioperatória da Sociedade Brasileira de Cardiologia. Arq. Bras. Cardiol. 2017;109(3 suppl 1):1-104. 3. Himes CP, Ganesh R, Wight EC, Simha V, Liebow M. Perioperative Evaluation and Management of Endocrine Disorders. Mayo Clin Proc. 2020 Dec;95(12):2760-2774.

Cardiol Therapeutics CEO David Elsley joined Steve Darling from Proactive with news the company has unveiled highly promising study results from international research, which showcased the remarkable potential of subcutaneously administered cannabidiol, the active pharmaceutical ingredient found in Cardiol's groundbreaking CRD-38 subcutaneous formulation. In this study, it was revealed that the application of subcutaneous cannabidiol effectively curtailed the upward trajectory of both body weight and heart weight, while also preventing undesirable increases in crucial cardiac inflammatory and remodelling markers. This research was conducted in a meticulously designed model of heart failure with preserved ejection fraction, noteworthy for its ability to accurately replicate the comorbidities commonly associated with this condition, such as hypertension, obesity, and metabolic dysfunction. David Elsley emphasized the profound significance of these study findings, particularly focusing on the unique pre-clinical model employed. This model, meticulously crafted to mimic the conditions experienced by patients suffering from heart failure with preserved ejection fraction, serves as an essential tool in understanding the complex interplay of factors contributing to the disease. The results, which illuminated the multiple cardioprotective effects of subcutaneously administered cannabidiol, serve as a pivotal stepping stone towards the development and potential approval of CRD-38 as a groundbreaking treatment for heart failure. The collective body of evidence generated by this research provides strong support for the advancement of Cardiol Therapeutics' innovative therapeutic approach in combating this debilitating condition, offering hope and potential relief to countless individuals affected by heart failure with preserved ejection fraction. #proactiveinvestors #cardioltherapeuticsinc #nasdaq #crdl #tsx #crdl #pharma #HeartFailure #MedicalInnovation #HealthcareAdvances #CRD38 #DavidElsley #HeartHealth #Obesity #MetabolicSyndrome #Hypertension #ClinicalResearch #MedicalScience #Inflammation #FibrosisTreatment #EjectionFraction #DiabetesRisk #MedicalDiscoveries #SubcutaneousMedicine #HealthTech #HealthcareNews #HeartDisease #ResearchResults #TreatmentBreakthrough #MedicalBreakthroughs #HealthcareIndustry #HealthcareRevolution#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Podcast Cardiopapers: 7 erros que já cometi em emergências cardiológicas by Cardiopapers

Nesse episódio Pâmela Valelongo fala sobre como estimar a probabilidade (suspeita) da patologia e a estratificação de risco no paciente com tromboembolismo pulmonar, que é a 3ª causa de morte cardiovascular no mundo . Você sabe quais escores utilizar para cada cenário? E como interpretá-los? Tema desafiador para quem trabalha na emergência e o Clube veio esclarecer os escores que geram muita confusão e deixar claro como classificar a gravidade do paciente com TEP, já que essa estratificação vai guiar a conduta terapêutica. Falando em emergência anota aí na sua agenda dia 04 de julho, terça-feira, às 20h no canal do Clube no YouTube vai ocorrer o PRÉ-LANÇAMENTO do SAFER: o curso de Emergências Cardiológicas do Clube da Cardio. Aperta o play!!A emergência é desafiadora, exige essas habilidades em um pacote só, e o nosso paciente, diversas vezes, não tem tempo, ele precisa de todos esse anos de conhecimento agora. O Clube da Cardio convida você a continuar se preparando SEMPRE para esse momento. “Como?” Com o SAFER, o método de ensino de emergências cardiovasculares do Clube da Cardio. Transforme seu conhecimento e sua prática com o SAFER e seja referência. Seja excelente! Torne-se EXCELENTE AGORA

Cardiol Therapeutics (WKN A2PA9E, ISIN CA14161Y2006, Symbol CT9) ist ein Life-Science-Unternehmen im klinischen Stadium, das sich auf die Behandlung von Herzerkrankungen konzentriert. „Das Team von Cardiol Therapeutics beschäftigt sich seit 30 Jahren mit Herzerkrankungen und der Entwicklung von Medikamenten gegen Herzerkrankungen. Wir entwickeln derzeit ein wichtiges Medikament für zwei sehr wichtige Krankheiten“, sagt David Elsley. Der Gründer und CEO des Unternehmens spricht über das Potenzial der Aktie. „Wir glauben, dass das Unternehmen derzeit dramatisch unterbewertet ist. Daher werden wir derzeit mit weniger als unserem Barwert gehandelt. Das Unternehmen ist sehr gut finanziert. Unsere Programme sind finanziert. Wir glauben, dass es eine Gelegenheit ist, sich auf der Investitionsseite zu beteiligen." Weitere Informationen auf https://www.cardiolrx.com

⁠DozeNews PRIME⁠: as melhores e mais didáticas revisões de cardiologia direto na sua caixa de entrada! Assine agora e tenha acesso à todo material já produzido! - ⁠https://dozeporoito.substack.com/

No início deste ano, tem causado preocupação o uso indiscriminado de semaglutida, princípio ativo do Ozempic, originalmente indicado para o tratamento do diabetes tipo 2 e depois reconhecido como eficiente na promoção do emagrecimento. Só no TikTok, vídeos sobre o Ozempic acumulam mais de 500 milhões de visualizações em todo o mundo. Na maioria, são mulheres que contam sua experiência ao usar o remédio para emagrecer rapidamente, muitas vezes sem acompanhamento médico nem alteração nos hábitos de vida. O tema foi debatido neste episódio do Podcast do Portal M!, que tem como convidada a médica endocrinologista Amana Matos. Ela faz parte do Núcleo de Obesidade do Centro de Referência Estadual para Assistência ao Diabetes e Endocrinologia (Cedeba). Amana também atende na Clínica Cardiológica da Pituba e no Centro de Diagnostico Integrado da Bahia (Cediba).

¿Se puede romper un corazón? La respuesta que dan desde la Sociedad Argentina de Cardiología (SAC) y la Fundación Cardiológica Argentina (FCA) es que sí. La expresión no es una leyenda; puede ocurrir y es importante saber de qué se trata para poder consultar a tiempo o ayudar a quien presenta estos síntomas.

¿Se puede romper un corazón? La respuesta que dan desde la Sociedad Argentina de Cardiología (SAC) y la Fundación Cardiológica Argentina (FCA) es que sí. La expresión no es una leyenda; puede ocurrir y es importante saber de qué se trata para poder consultar a tiempo o ayudar a quien presenta estos síntomas.

Cardiol Therapeutics CEO David Elsley joined Steve Darling from Proactive to share news the company has announced the beginning of a Phase II open-label pilot study which will investigate the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis. Elsley telling Proactive study will evaluate the use of CardiolRx as a novel therapy for pericarditis. The study is expected to enroll 25 patients at clinical centers in the United States that specialize in pericarditis care. #proactiveinvestors #cardioltherapeuticsinc #nasdaq #crdl #tsx #crdl #pharma #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Debate da Super Manhã: No debate desta sexta-feira (02), o comunicador Wagner Gomes conversa com especialistas sobre os comportamentos contemporâneos que podem interferir no bem-estar e na longevidade. Participam, o Endocrinologista atuante nos hospitais Osvaldo Cruz e IMIP, Fábio Moura, o Cardiologista clínico, Coordenador do Setor de Internamento da Emergência Cardiológica e Preceptor de Residência no Pronto-Socorro Cardiológico Universitário de Pernambuco - PROCAPE, Humberto Caldas, e o Psicólogo, Professor da Faculdade de Ciências Médicas da Universidade de Pernambuco, Doutor em Neuropsiquiatria e Pós-Doutor em Ciências da Saúde, Spencer Júnior.

ANDRÉ PEPES ENTREVISTA O CARDIOLOGISTA DR. IURI CANDIAGO PARA FALAR SOBRE: SÉRIE EXAMES CARDIOLÓGICOS: HOLTER --- Send in a voice message: https://anchor.fm/saudeemfoco/message

Dr. Arpit Sothwal, a new clinician at St. Luke's Heart Care Clinic, joins Dr. Arnold to talk about his background, clinical and personal interests, what led him to UnityPoint Health and much more.To schedule an appointment with Dr. Sothwal, call St. Luke's Heart Care Clinic at (319) 364-7101 .This is another episode in a new segment on the podcast called "New Clinician Spotlight." In these episodes, Dr. Arnold will sit down with new clinicians at UnityPoint Health - Cedar Rapids and get to know them as a clinician and as a person.Do you have a question about a trending medical topic? Ask Dr. Arnold! Anything from COVID-19 to the latest technologies and procedures to general questions about a service provided at UnityPoint Health - Cedar Rapids. Submit your question and it may be answered by Dr. Arnold on the podcast! Submit your questions at: https://www.unitypoint.org/cedarrapids/submit-a-question-for-the-mailbag.aspx

Cardiol Therapeutics CEO David Elsley joined Steve Darling from Proactive to share news the company has announced the first patient has been enrolled in ARCHER which is a Phase 2 double-blind, randomized, placebo-controlled trial of CardiolRX. Elsley telling Proactive, this study is designed to study the safety and tolerability of CardiolRX and to also see the impact on patients presenting with acute myocarditis.

ANDRÉ PEPES ENTREVISTA O CARDIOLOGISTA DR. IURI CANDIAGO PARA FALAR SOBRE: EXAMES CARDIOLÓGICOS - MAPA DE HORAS 24hs --- Send in a voice message: https://anchor.fm/saudeemfoco/message

Cardiol Therapeutics CEO David Elsley joined Steve Darling from Proactive to share news the company has been granted authorization by the U.S. Food and Drug Administration for the Company's Investigational New Drug Application in relation to CardiolRx. Elsley telling Proactive this will allow the company to begin a Phase II open-label pilot study designed to evaluate the tolerance and safety of CardiolRx is use for Recurrent pericarditis.

O retorno do bolus com Joanne e Marcela falando sobre AAS na profilaxia primária para doença cardiovascular (DCV)! Elas abordam 3 tópicos: - História de AAS na prevenção de DCV - Recomendação atual e os principais estudos que motivaram a mudança de recomendação (ASPREE, ARRIVE E ASCEND) - O que fazer com quem já usa? Tá imperdível! Referências: 1. Aimo A, De Caterina R. Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. Anatol J Cardiol. 2020;23(2):70-78. 2. Berger JS. Aspirin for Primary Prevention—Time to Rethink Our Approach. JAMA Netw Open.2022;5(4):e2210144. 3. Bowman L, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379:1529-1539 4. Chiang KF, Shah SJ, Stafford RS. A Practical Approach to Low-Dose Aspirin for Primary Prevention. JAMA. 2019;322(4):301-302 5. Gaziano JM, et al. Aspirin to Reduce Risk of Initial Vascular Events - ARRIVE. Lancet 2018; 392: 1036–46 6. McNeil JJ, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med 2018; 379:1519-1528 7. Précoma DB, Oliveira GMM, Simão AF, Dutra OP, Coelho OR, Izar MCO, Póvoa RMS, et al. Atualização da Diretriz de Prevenção Cardiovascular da Sociedade Brasileira de Cardiologia – 2019. Arq. Bras. Cardiol. 2019;113(4):787-891 8. Raber I, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 2019; 393: 2155–67 9. US Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA.2022;327(16):1577–1584.

Entrevista al Dr juan Francisco Pettit cardiólogo especialista en jovenes y niños quien nos estará hablando un poco de como debe ser el cuidado de los niños que padecen el síndrome de Down, no te pierdas este excelente contenido el cual puede ser de gran ayuda. Moderadora: María Cariné Navas Invitado: Dr juan Francisco Pettit Programa Tiempo de Bienestar Casa de emision: Top radio 88.5 fm www.publisitetk.com Todos los derechos reservados --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/publisite-xtreme/support

Nesta edição do Consultório CBN, Henrique Bonaldi esclarece como funcionam os principais exames cardíacos que são realizados pelos médicos. Ouça!

El presidente de la Fundación Cardiológica Argentina se refirió a la nueva variante Ómicron, detectada originalmente en Sudáfrica, y dijo que "es preocupante". "Tiene tantas mutaciones que le permite entrar en muchos lugares", dijo. "Lo que se está haciendo es que esa variante se expanda", expresó en referencia a que el Gobierno dispuso hoy que todas las personas que ingresen al país procedentes de África o que hayan estado en el continente africano en los últimos 14 días previos a su llegada a la Argentina deberán realizar un aislamiento obligatorio.

Federico, Isabel González y el Dr. Enrique de la Morena hablan con el especialista en Cardiología Miguel Orejas.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to share news the company has closed their public offering of 16,350,000 units of the Company for a price of US$3.07 per share for gross proceeds of just over 50 million U.S. . Elsley telling Proactive the demand they saw during the capital raise and where this puts the company in their sector. He also talks about how they plan on using that money as they continue down the road of clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease.

Cardiol Therapeutics CEO David Elsley joined Proactive's Stephen Gunnion with the news that the company is expanding its LANCER Phase II/III clinical trial to Brazil, Mexico and Canada, having run the trial exclusively in the United States until now. Elsley telling Proactive that with coronavirus (COVID-19) there's an urgent need to develop new therapeutics to address the immune-mediated inflammation that results from the virus, particularly in high-risk patients with cardiovascular disease.

Nesta entrevista incrível a Técnica de Enfermagem Giullia Capella conta os detalhes de com é atuar na UTI Pediátrica, com foco nos pacientes cardiológicos. Que aula! Que profissional!!! Anota todos os detalhes e siga estes conselhos. Certamente você terá uma carreira de sucesso na Enfermagem. Instagram: @nursecastbr Nossa entrevistada @giulliacapella. #enfermagem #uti #pediatria #tecnicodeenfermagem

ANDRÉ PEPES RECEBE O CARDIOLOGISTA DR. IURI CANDIAGO, PARA FALAR SOBRE: EXAMES CARDIOLÓGICOS, QUAIS SÃO E PRA QUE SERVEM? PARTE II --- Send in a voice message: https://anchor.fm/saudeemfoco/message

Médico cardiólogo (MN 58310), ex presidente de la Sociedad Argentina de Cardiología y de la Fundación Cardiológica Argentina. Hoy miembro de la American College of Cardiology (EEUU).

ANDRÉ PEPES RECEBE O CARDIOLOGISTA DR. IURI CANDIAGO, PARA FALAR SOBRE: EXAMES CARDIOLÓGICOS, QUAIS SÃO E PRA QUE SERVEM? --- Send in a voice message: https://anchor.fm/saudeemfoco/message

Mateus Prata está novamente acompanhado de Rapha Rossi, dessa vez contando com a presença de Diandro Mota, para discutir quando internar um paciente com dor torácica na emergência, pensando em Síndrome Coronariana Aguda. Se ainda não ouviu o episódio anterior sobre os escores prognósticos, não perca! Hoje mostraremos como usá-los para auxiliar a decisão de internar ou não o paciente. Referências:

El examen de rutina del pediatra (al menos una vez al año) es clave para detectar una patología cardíaca. Y son varios los síntomas ante los cuales un niño deber ser evaluado por un especialista. En su columna de todos los lunes, en Buenas Notas, el doctor Ramón Álvarez, responde seis preguntas recurrentes sobre cardiología infantil. Escuchá la nota aquí:

Cardiol Therapeutics CEO David Elsley joined Steve Darling from Proactive to bring news the company has hit a major corporate milestone as they begin trading on the Nasdaq Exchange under the ticker “CRDL” Elsley telling Proactive the company will continue to trade on the Toronto Stock Exchange with the ticker “CRDL” Elsley also shared why this is so big for Cardiol because the NASDAQ is the premier global stock exchange for life science and biotechnology companies.

El Cardiólogo Intervencionista y Presidente del Colegio de Cardiólogos de Jalisco A.C. Luis Virgen Carrillo, nos explica qué es el cateterismo, un procedimiento que se usa para diagnosticar y tratar ciertas enfermedades cardiovasculares, en qué casos se utiliza y cómo se realiza. Citas al teléfono 3338131040, además síguelo en redes sociales como Luis Virgen Cardiólogo.

Dr. Abrão Cury, Diretor da Sociedade Brasileira de Clínica Médica, Cardiologista e Clínico Geral

"Creo que el fútbol tiene que revaluar sus protocolos rápidamente. Es un momento que tienen que pensar qué hacer. Hoy por hoy el fútbol es un negocio muy peligroso, no se puede subestimar a esta enfermedad. Dije desde el principio que no se debería haber jugado la Copa América en Argentina y mucho menos en Brasil. Fijate los errores que hay en el fútbol y la cantidad de jugadores contagiados", dijo Jorge Tartaglione, pte. de la Fundación Cardiológica Argentina, en De Acá en Más. Agregó: "El cuidado es muy importante. Es importante que se controlen. Si tuvieron Covid, que no empiecen a hacer deporte inmediatamente. El virus es el maestro del engaño y un asesino en fuga". --- Send in a voice message: https://anchor.fm/urbanaplayfm/message

O médico cardiologista, Dr. Paulo Saraiva, traz orientações sobre os cuidados com a saúde do coração e alerta que aumentaram número de óbitos de pacientes cardio

“La especialización de quienes trabajan en las unidades de cuidados intensivos es fundamental para mejorar los resultados en salud”. Así lo expresa de forma emocionada en Fórmula Salud Victoria Trasmonte, intensivista de la Unidad de Cuidados Críticos Cardiológicos del 12 de Octubre. Aunque la tecnología de estas unidades es máxima, eso no debe hacernos perder la importancia del contacto humano, del trato cuidadoso y sincero de quienes trabajan en ellas y que durante la primera ola de esta pandemia del COVID-19 tuvieron que tomar decisiones límite para decidir, en la frontera ética y deontológica, quienes podían acceder y quienes no. “Ahora en las UCI los pacientes son más jóvenes, pero en muchos casos seguimos viendo personas que por miedo a ir al hospital ingresan con la enfermedad más avanzada y con peor pronóstico. Un tratamiento precoz favorece la buena evolución del paciente”.

“Se pudo hacer”, así resume Victoria Trasmonte, intensivista de la Unidad de Cuidados Críticos Cardiológicos del 12 de Octubre lo que vivieron desde dentro de las UCI de su hospital durante los peores momentos de la pandemia y que ha supuesto un espaldarazo a las iniciativas para humanizar estas áreas críticas de los hospitales. “El secreto de la sanidad española es el valor humano de los que la componen” “La semana pasada –nos cuenta en Fórmula Salud– viví una experiencia enternecedora cuando una mujer embarazada de 32 semanas ingresó en nuestro hospital afectada por el virus. Se le practicó cesárea e ingresó en nuestra Unidad. Con signos de desorientación, pensando que había perdido a su bebé, conseguimos calmarla y grabamos un vídeo mostrándole a su recién nacido y casi de forma automática mejoró su estado y pocas horas después salió de nuestra UCI. Ver a su bebé a través de una Tablet fue la mejor medicina posible” “Hay que dotar a las UCI de más personal y cuidarlos y valorarlos como se merecen”

Con un 15% de las camas de hospital y más del 40% de las camas de UCI ocupadas por pacientes COVID en Madrid, el ritmo de vacunación batiendo récords diarios nos permite obtener una fotografía de la pandemia en nuestra región más positiva que en las últimas semanas. Pese a todo, siguen las unidades de pacientes críticos muy tensionadas y por eso vamos a conocer al detalle cómo es el trabajo de los intensivistas atendiendo a pacientes Covid y no Covid con una experta, Victoria Trasmonte, intensivista de la Unidad de Cuidados Críticos Cardiológicos del 12 de Octubre. Antes nos interesamos por el futuro de la farmacia en tiempos de pandemia con Jesús Aguilar, reelegido presidente del Consejo General de Colegios Oficiales de Farmacéuticos para un próximo mandato.

El día que dimos la primera alta de la UCI a un paciente COVID durante la primera ola de la pandemia grabamos el primer vídeo para que pacientes y familiares pudieran comunicarse y reducir la angustia por no poder verse físicamente en el hospital”, así lo cuenta en Fórmula Salud Victoria Trasmonte, intensivista de la Unidad de Cuidados Críticos Cardiológicos del 12 de Octubre. El miedo no se nos borrará nunca de nuestra mente Y así nació un proyecto original que, desde el 12 de Octubre se extendió a otro hospitales de Madrid, de España y del mundo para “acortar” distancias entre los pacientes críticos y sus familiares cuando ninguno de estos podía visitar a los hospitalizados y menos aún a quienes ingresaban en las UCI. No podía ser que los pacientes se nos murieran en soledad Esa fue una iniciativa que contribuyó a humanizar en situaciones excepcionales las unidades de pacientes críticos y en la que los intensivistas de este hospital madrileño jugaron un papel muy destacado.

Cardiol Therapeutics $CRDL.ca $CRTPF is a groundbreaking, clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels). The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™, in treating hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP and THC free. Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35. The company is also developing proprietary cannabidiol formulations for the treatment of chronic heart failure. One such key development is its commercial product, Cortalex™, an extra-strength formulation (100 mg/mL concentration) of cannabidiol oil that is pharmaceutically produced to be free of THC. Cardiol believes Cortalex™ to be the purest form of cannabidiol oil available in Canada. It is the first THC-free extra-strength formulation of cannabidiol oil available across Canada exclusively online at Medical Cannabis by Canada’s largest pharmacy retailer, Shoppers Drugs Mart. In March 2020, Cardiol signed a supplier agreement to become a medical cannabidiol supplier to Shoppers Drug Mart. The retailer will supply Cardiol’s pharmaceutical cannabidiol products to Shoppers for sale in all provinces and territories in Canada through Shoppers’ online store, Medical Cannabis by Shoppers. And there’s plenty more to write home about: ~ $27M from exercise of warrants + equity raise since June 2020 Uplisting to NASDAQ Team expansion with Chief Medical Officer hire David Elsley, Cardiol Therapeutics’ President & CEO, gives us the low-down. Check it out:

Cardiol Therapeutics Inc (TSX:CRDL) (OTCQX:CRTPF) CEO Larry Reaugh talks to Proactive about the Oakville, Ontario-based group's clinical studies aimed at treating heart disease and the coronavirus. Reaugh says next steps for its Phase 1 study to treat heart disease that the group recently completed, will underpin the filing of its second IND with the FDA to advance the trial further.

¿Qué es un gato hipertenso? Diagnóstico diferencial. Signos cardiológicos de hipertensión. Soplo como signo clave. Tratamiento. Autor: Fidel Causse del Río, LV, Postgrado en Oftalmología Veterinaria por Universidad Autónoma de Barcelona, Animal Visión, Málaga

Compacto de entrevista com a abordagem de temas pertinentes à comunidade do Vale do Rio Pardo e Taquari. A cada edição um tema relevante ou algum assunto específico de ampla repercussão. 

Compacto de entrevista com a abordagem de temas pertinentes à comunidade do Vale do Rio Pardo e Taquari. A cada edição um tema relevante ou algum assunto específico de ampla repercussão.

Panamá, 12 de marzo de 2020.La prevención primaria con la aspirina no se debe utilizar, solo pacientes con padecimientos cardiovasculares recetados por sus médicos. Así lo manifestó el Presidente de la Fundación Cardiológica de Panamá, Alfaro Marchena.No produce ningún beneficio, puede causar sangrado.Según estudios realizados a nivel internacional el riesgo de sufrir una hemorragia interna, uno de los efectos secundarios de la aspirina, es muy alto entre quienes la toman todos los días.Su utilización descontrolada se basa en que el fármaco previene la formación de coágulos en las venas y arterias evitando que las plaquetas que circulan en la sangre se mantengan unidas. Al reducir la formación de coágulos, las tabletas reducen el riesgo de sufrir otro evento cardiovascular.

A síndrome do coração partido é um problema raro que provoca sintomas semelhantes aos de infarto, como dor no peito, falta de ar ou cansaço que podem surgir em períodos de estresse emocional intenso, como um processo de separação ou após o falecimento de um familiar, por exemplo. Para falar sobre o assunto, Jota Batista conversa no Canal Saúde com o cardiologista da UDC – Unidade de Diagnóstico Cardiológico do Recife, Otacílio Araújo.

¿Por qué es importante hacerse un chequeo cardiológico a inicio de año? El Cardiólogo Intervencionista y Presidente del Colegio de Cardiólogos de Jalisco A.C., el Dr. Luis Virgen Carrillo, nos comparte cuándo es un buen momento para checarnos con el médico y qué exámenes del corazón realizarnos a inicio de año. Haz tu cita con él al teléfono 3338131040 y síguelo en redes sociales como Luis Virgen Cardiólogo.

Dr. David Heredia Dr. Leonell Freytes Fellows Cardiológia Tema: Historia de éxito en Educación Médica Graduada San Lucas

01-feb-2021 / Chequeo Cardiológico que debemos hacernos para conocer el estado de nuestro corazón ❤️ ¿Por qué es importante hacerse un chequeo cardiológico a inicio de año? El Cardiólogo Intervencionista y Presidente del Colegio de Cardiólogos de Jalisco A.C., el Dr. Luis Virgen Carrillo, nos comparte cuándo es un buen momento para checarnos con el médico y qué exámenes del corazón realizarnos a inicio de año. Haz tu cita con él al teléfono 3338131040 y síguelo en redes sociales como Luis Virgen Cardiólogo. ¿Quieres iniciar este 2021 haciéndote un chequeo médico totalmente GRATIS? *Sigue en Facebook la cuenta de Facebook/ Dr. Luis Virgen *Ingresar a esta publicación www.facebook.com/Drluisvirgen/posts/3714503441920820 *Dale like a la publicación del "GIVEAWAY" y etiqueta a una persona (puedes participar cuantas veces quieras mientras las dos personas cumplen todos los pasos *Menciona por qué o para quién quieres ganar este chequeo médico.

¿Por qué es importante hacerse un chequeo cardiológico a inicio de año? El Cardiólogo Intervencionista y Presidente del Colegio de Cardiólogos de Jalisco A.C., el Dr. Luis Virgen Carrillo, nos comparte cuándo es un buen momento para checarnos con el médico y qué exámenes del corazón realizarnos a inicio de año. Haz tu cita con él al teléfono 3338131040 y síguelo en redes sociales como Luis Virgen Cardiólogo. ¿Quieres iniciar este 2021 haciéndote un chequeo médico totalmente GRATIS? *Sigue en Facebook la cuenta de Facebook/ Dr. Luis Virgen *Ingresar a esta publicación www.facebook.com/Drluisvirgen/posts/3714503441920820 *Dale like a la publicación del "GIVEAWAY" y etiqueta a una persona (puedes participar cuantas veces quieras mientras las dos personas cumplen todos los pasos *Menciona por qué o para quién quieres ganar este chequeo médico.

Apresentação: Sabrina RibeiroInstagram @papopaliativoTwitter @papo_paliativoConvidado:Ricardo Tavares Siga também a ANCP em suas redes sociais:https://www.facebook.com/ANCPaliativoshttps://twitter.com/ancpaliativoshttps://www.youtube.com/user/TVANCP/https://www.linkedin.com/company/ancp/Quem tiver interesse em enviar seus comentários, sugestões de temas e participantes para o Podcast basta enviar um e-mail para pallicast.ancp@paliativo.org.brCHAMADA Cuidados Paliativos, segundo definição da Organização Mundial da Saúde (OMS), trata-se de uma “Assistência promovida por uma equipe multidisciplinar, que objetiva a melhoria da qualidade de vida do paciente e de seus familiares, diante de uma doença ou agravo que ameace a continuidade da vida, por meio da prevenção e do alívio do sofrimento, da identificação precoce, avaliação impecável e tratamento da DOR e demais sintomas físicos, sociais, psicológicos e espirituais desde o diagnóstico da doença ao final da vida e estendendo-se ao período de luto”. Identificar na cardiologia quais pacientes devem receber atendimento de Cuidados Paliativos, é um desafio, pois muitos especialistas ainda têm uma visão equivocada, sem relacionar esse cuidado a melhoria da qualidade de vida do paciente cardiopata. Neste episódio do Pallicast Ricardo Tavares, médico cardiologista, intensivista e coordenador do núcleo de Cuidados Paliativos do Hospital das Clínicas da Faculdade de Medicina da USP (HC-FMUSP) compartilha sua experiência. Informamos que a opinião do entrevistado não necessariamente reflete a opinião da ANCP.SUGESTÕES DO ENTREVISTADOLivro Fragmentos de Um Ensinamento Desconhecido: em Busca do Milagroso por P. D. Ouspensky DIRECIONAMENTO METADADOS#conferenciafamiliar #familyconference #cuidadopaliativo #palliativecare #epec #shareddecision #healthcareteam #socialservice #servicosocial #GOC #goalsofcare #bioetica #bioethics #decisaocompartilhada #intubação #rebaixamento #idosos #elderly #humanização #comunicação #escuta #decisaocompartilhada #trabalhoemequipe #medicina #serviçosocial #cuidadohumanizado #escutaativa #ANCPaliativos #shareddecisionmaking #goalsofcare #vidapaliativa #beneficencia #naomaleficencia #PalliativeCareinCardiology #Cardiology #cardiologypalliativecare

Dr Thiago Dutra fala sobre a importância do exame cardiológico pós-covid19. Anomalia no miocárdio em pacientes Covid, tem se mostrado consistentes em estudos científicos. Gostou? Pague um cafezinho pra gente: https://apoia.se/bgscast. Apresentação Larissa Face Kuvabara. Participação: Dr Thiago Dutra. --- Send in a voice message: https://anchor.fm/bgscast/message Support this podcast: https://anchor.fm/bgscast/support

Jorge Tartaglione ejerce como médico cardiólogo hace más de treinta años. En la actualidad es presidente de la Fundación Cardiológica Argentina y coordinador médico de la campaña nacional de reanimación cardiopulmonar que se realiza en las escuelas dependientes del Ministerio de Educación de la Nación. Hablamos de Covid-19

Na nossa coluna Saúde de hoje, dia do cardiologista 14.08, Dr Vinícius Narciso fala sobre a necessidade do Check-up cardiológico. A coluna Saúde vai ao ar todas as sextas feiras no programa ALMA DE CAMPO. Na www.radiosul.net ou pelo nosso APP

#214 - Erro em preop: suspender medicações cardiológicas no dia da cirurgia! by Cardiopapers

Esta semana, estamos com um programa de podcast especial sobre coronavírus. Em cada episódio, um por dia da semana, um de nossos editores médicos ou conteudistas vai falar sobre o que se sabe até agora da Covid-19 em sua área. Hoje, o cardiologista Gabriel Quintino, conteudista do Whitebook, trouxe os principais pontos da abordagem cardiológica do paciente, como aumento de troponina como mau prognóstico e relação do uso de cloroquina com azitromicina no tratamento e possível prolongamento de QT. Você que é ouvinte dos podcasts da PEBMED tem um desconto de 20% no Whitebook! Baixe o aplicativo e insira o cupom PEBPODCAST no pagamento da assinatura.

Hablamos con el Dr. Jorge Tartaglione, (MN 67502), presidente de la Fundación Cardiológica Argentina

¡Gracias por escuchar! Los medicamentos antimaláricos, hidroxicloroquina y cloroquina, son fármacos moduladores de las enfermedades reumáticas introducidos por serendipia y empíricamente para el tratamiento de diversas enfermedades reumáticas. Ni la cloroquina ni la hidroxicloroquina se sometieron al proceso de desarrollo de fármacos convencional, pero su uso se ha convertido en parte importante de los tratamiento actuales para la artritis reumatoide, lupus eritematoso sistémico, síndrome de anticuerpos antifosfolípido y síndrome de Sjögren primario. En este episodio exploraremos sus principales características desde la perspectiva farmacológica.Les pido amablemente dejen sus comentarios en tukua.podbean.com y la calificación a este y otros episodios en iTunes.Estas son algunas referencias de utilidad:Ruiz-Irastorza, G. et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69, 20–28 (2010).Ostensen, M. et al. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology 50, 657–664 (2011).Akhavan, P. S. et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.Ponticelli, C. & Moroni, G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert. Opin. Drug Saf. 16, 411–419 (2017).Wang, S. Q. et al. Is hydroxychloroquine effective in treating primary Sjogren’s syndrome: a systematic review and meta-analysis. BMC Musculoskelet. Disord. 18, 186 (2017).Rainsford, K. D. et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23, 231–269 (2015).Collins, K. P., Jackson, K. M. & Gustafson, D. L. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancerrelated autophagy modulation. J. Pharmacol. Exp. Ther. 365, 447–459 (2018).Munster, T. et al. Hydroxychloroquine concentrationresponse relationships in patients with rheumatoid arthritis. Arthritis Rheum. 46, 1460–1469 (2002).Carmichael, S. J., Charles, B. & Tett, S. E. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther. Drug Monit. 25, 671–681 (2003).Mok, C. C., Mak, A. & Ma, K. M. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14, 106–112 (2005).Petri, M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr. Rheumatol. Rep. 13, 77–80 (2011).Kingsbury, S. R. et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann. Intern. Med. 168, 385–395 (2018).Lee, W. et al. Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebocontrolled trial. Arthritis Care Res. 70, 1320–1325 (2018).Rempenault, C. et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 77, 98–103 (2018).Ruiz-Irastorza, G. et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res. Ther. 11, R109 (2009).Flannery, E. L., Chatterjee, A. K. & Winzeler, E. A. Antimalarial drug discovery – approaches and progress towards new medicines. Nat. Rev. Microbiol. 11, 849–862 (2013).Ridley, R. G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415, 686–693 (2002).Minie, M. et al. CANDO and the infinite drug discovery frontier. Drug Discov. Today 19, 1353–1363 (2014).Paddon, C. J. et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496, 528–532 (2013).Hale, V. et al. Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs. Am. J. Trop. Med. Hyg. 77, 198–202 (2007).Somer, M. et al. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br. J. Clin. Pharmacol. 49, 549–554 (2000).Kormelink, T. G. et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann. Rheum. Dis. 69, 2137–2144 (2010).Toimela, T., Tahti, H. & Salminen, L. Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Ophthalmic Res. 27, 150–153 (1995).Bannwarth, B. et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet. 30, 194–210 (1996).Carmichael, S. J. et al. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J. Rheumatol. 29, 2077–2083 (2002).van den Borne, B. E. et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J. Rheumatol. 25, 1493–1498 (1998).Namazi, M. R. The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine. Lupus 18, 104–105 (2009).Jallouli, M. et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 67, 2176–2184 (2015).Ezra, N. & Jorizzo, J. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. Clin. Exp. Dermatol. 37, 327–334 (2012).Yeon Lee, J. et al. Factors related to blood hydroxychloroquine concentration in patients with systemic lupus erythematosus. Arthritis Care Res. 69, 536–542 (2017).Borden, M. B. & Parke, A. L. Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf. 24, 1055–1063 (2001).Costedoat-Chalumeau, N. et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun. Rev. 4, 111–115 (2005).Teng, Y. K. O. et al. An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. Rheumatology 57, 1707–1720 (2017).Andreoli, L. et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 76, 476–485 (2017).Gotestam Skorpen, C. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann. Rheum. Dis. 75, 795–810 (2016).Izmirly, P. M. et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 126, 76–82 (2012).Saxena, A. et al. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol. Rev. 22, 263–267 (2014).Friedman, D. et al. No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. Clin. Exp. Rheumatol. 35, 857–859 (2017).Sammaritano, L. R. & Bermas, B. L. Rheumatoid arthritis medications and lactation. Curr. Opin. Rheumatol. 26, 354–360 (2014).An, J. et al. Antimalarial drugs as immune modulators: new mechanisms for old drugs. Annu. Rev. Med. 68, 317–330 (2017).An, J. et al. Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction. J. Immunol. 194, 4089–4093 (2015).van den Borne, B. E. et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cellFasano, S. et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J. Rheumatol. 44, 1032–1038 (2017).Towers, C. G. & Thorburn, A. Therapeutic targeting of autophagy. EBioMedicine 14, 15–23 (2016).Rand, J. H. et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibodyβ2-glycoprotein I complexes to phospholipid bilayers. Blood 112, 1687–1695 (2008).Jancinova, V., Nosal, R. & Petrikova, M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb. Res. 74, 495–504 (1994).Bertrand, E. et al. Antiaggregation action of chloroquine. Med. Trop. 50, 143–146 (1990).Nosal, R., Jancinova, V. & Petrikova, M. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb. Res. 77, 531–542 (1995).Lazarus, M. N. et al. Incidence of cancer in a cohort of patients with primary Sjogren’s syndrome. Rheumatology 45, 1012–1015 (2006). J. Rheumatol. 21, 375–376 (1994).Wallace, D. J. et al. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2, S13–S15 (1993).Hjorton, K. et al. Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. Arthritis Res. Ther. 20, 238 (2018).Willis, R. et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21, 830–835 (2012).Wu, S. F. et al. Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res. Ther. 19, 183 (2017).Qushmaq, N. A. & Al-Emadi, S. A. Review on effectiveness of primary prophylaxis in aPLs with and without risk factors for thrombosis: efficacy and safety. ISRN Rheumatol. 2014, 348726 (2014).Nuri, E. et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol. Res. 65, 17–24 (2017).Dadoun, S. et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 80, 29–33 (2013).van den Hoek, J. et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol. Int. 37, 487–493 (2017).Avina-Zubieta, J. A. et al. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res. 69, 849–856. (2017).Srinivasa, A., Tosounidou, S. & Gordon, C. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? J. Rheumatol. 44, 398 (2017).Abdel-Hamid, H., Oddis, C. V. & Lacomis, D. Severe hydroxychloroquine myopathy. Muscle Nerve 38, 1206–1210 (2008).Jafri, K. et al. Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review. Clin. Rheumatol. 36, 1437–1444 (2017).Khosa, S. et al. Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. Neuropathology 38, 646–652 (2018).Stein, M., Bell, M. J. & Ang, L. C. Hydroxychloroquine neuromyotoxicity. J. Rheumatol. 27, 2927–2931 (2000). Int. J. Cardiol. 157, 117–119 (2012).Sundelin, S. P. & Terman, A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 110, 481–489 (2002).Jorge, A. et al. Hydroxychloroquine retinopathy implications of research advances for rheumatology care. Nat. Rev. Rheumatol. 14, 693–703 (2018).Marmor, M. F. et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 123, 1386–1394 (2016).Yusuf, I. H. et al. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye 32, 1168–1173 (2018). J. Rheumatol. 44 1841–1849 (2017).Padol, I. T. & Hunt, R. H. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidencebased interpretation. Rheumatology 49, 837–843 (2010).Hage, M. P., Al-Badri, M. R. & Azar, S. T. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther. Adv. Endocrinol. Metab. 5, 77–85 (2014).Costedoat-Chalumeau, N. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 3284–3290 (2006).Costedoat-Chalumeau, N. et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin. Pharmacol. Ther. 103, 1074–1082 (2018).Bethel, M. et al. Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease. J. Investig. Med. 64, 908–910 (2016).Sperati, C. J. & Rosenberg, A. Z. Hydroxychloroquineinduced mimic of renal Fabry disease. Kidney Int. 94, 634 (2018).Yusuf, I. H., Lotery, A. J. & Ardern-Jones, M. R. Joint recommendations for retinal screening in longterm users of hydroxychloroquine and chloroquine in the United Kingdom, 2018. Br. J. Dermatol. 179, 995–996 (2018).Melles, R. B. & Marmor, M. F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132, 1453–1460 (2014).Costedoat-Chalumeau, N., Isenberg, D. & Petri, M. Letter in response to the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019215573 (2019).

¡Gracias por escuchar!Para empezar el año, este episodio lo dedicaré a hablar de como la composición corporal influye sobre la eficacia y eventos adversos asociados al uso de glucocorticoides.Agradezco su continuada atención a este podcast y les recuerdo que se pueden suscribir a el en iTunes, Spotify o usando su gestor de podcasts favorito. Como siempre su retroalimentación es bienvenida y les pido amablemente dejen su calificación a este y otros episodios en iTunes.Estas son algunas de las referencias consultadas para este episodio:van der Goes, M. C. et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 69, 1015–1021 (2010).Konijn, N. P. et al. The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis. Rheumatology (Oxford) http://dx.doi.org/10.1093/ rheumatology/kew221 (2016).Buttgereit, F., Smolen, J. S., Coogan, A. N. & Cajochen, C. Clocking in: chronobiology in rheumatoid arthritis. Nat. Rev. Rheumatol. 11, 349–356 (2015).Arvidson, N. G., Gudbjornsson, B., Larsson, A. Hallgren, R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann. Rheum. Dis. 56, 27–31 (1997).Cutolo, M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD Open 2, e000203 (2016).Smith-Ryan, A. E. et al. Validity and reliability of a 4-compartment body composition model using dual energy X-ray absorptiometry-derived body volume. Clin. Nutr. http://dx.doi.org/10.1016/j. clnu.2016.05.006 (2016).Summers, G. D., Metsios, G. S., Stavropoulos- Kalinoglou, A. & Kitas, G. D. Rheumatoid cachexia and cardiovascular disease. Nat. Rev. Rheumatol. 6, 445–451 (2010).Walsmith, J. & Roubenoff, R. Cachexia in rheumatoid arthritis. Int. J. Cardiol. 85, 89–99 (2002).Arshad, A., Rashid, R. & Benjamin, K. The effect of disease activity on fat-free mass and resting energy expenditure in patients with rheumatoid arthritis versus noninflammatory arthropathies/soft tissue rheumatism. Mod. Rheumatol. 17, 470–475 (2007).Elkan, A. C., Hakansson, N., Frostegard, J., Cederholm, T. & Hafstrom, I. Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res. Ther. 11, R37 (2009).

No episódio de hoje o Dr. Eduardo Pereira recebe o Cardiologista, o Dr. Idemasio Sorato Balbino, e vão nos contar um pouco sobre o Check up cardiológico.

Acesse a revista Residência Pediátrica: residenciapediatrica.com.br/

#33 - qual o erro mais comum em emergências cardiológicas?

Gracias por escuchar. Estas son los artículos a los que se hace referencia en este episodio del podcast:Ogdie, A. et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann. Rheum. Dis. 74, 326–332 (2014).Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J. & Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoidarthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 71, 1524–1529 (2012).Schieir, O., Tosevski, C., Glazier, R. H., Hogg-Johnson, S.& Badley, E. M. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann. Rheum. Dis. 76, 1396–1404 (2017). 21.D’Agostino, R. B. et al. General cardiovascular risk profile for use in primary care. Circulation 117, 743–753 (2008).Arts, E. E. A. et al. Performance of four current risk 23. algorithms in predicting cardiovascular events inpatients with early rheumatoid arthritis. Ann. Rheum.Dis. 74, 668–674 (2015). 24.Crowson, C. S., Matteson, E. L., Roger, V. L., Therneau, T. M. & Gabriel, S. E. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am. J. Cardiol. 110, 420–424 (2012). 25.Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms ofinflammatory joint disorders: 2015/2016 update. 26. Ann. Rheum. Dis. 76, 17–28 (2017).Gómez-Vaquero, C. et al. SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis 27. Res. Ther. 15, R91 (2013).Ahlehoff, O. et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J. Intern. Med. 270, 147–157 (2011).Polachek, A., Touma, Z., Anderson, M. & Eder, L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res. 69, 67–74 (2017).Gulati, A. M. et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. Ann. Rheum. Dis. 75, 819–824 (2016).Eder, L., Wu, Y., Chandran, V., Cook, R. & Gladman, D. D. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann. Rheum. Dis. 75, 1680–1686 (2016).Eder, L. et al. Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study.J. Rheumatol. 45, 378–384 (2018).Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P. & Hennekens, C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973–979 (1997).Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).Sever, P. S. et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo- Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J. Am. Coll. Cardiol. 62, 717–729 (2013).Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019).Szentpetery, A. et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol. 70, 396–407 (2018).Min, J. K. et al. Relationship of coronary artery plaque composition to coronary artery stenosis severity: results from the prospective multicenter ACCURACY trial. Atherosclerosis 219, 573–578 (2011).

La Dra. Gladys Atobe del Instituto de Diagnósticos por Imágenes, del  Centro Médico Bautista, especialidad » Ecocardiografia Doppler, Eco Transesofagica, Eco stress con ejecicios y Eco dopler de Carotidas y Vertebrales» nos habla acerca de los estudios Cardiológicos no invasivos Si usted desea agendar citas para consultas lo puede hacer al número (021) 688 9000. Para mas informaciones visite la página La entrada Estudios Cardiológicos no invasivos se publicó primero en Obedira.

La 26827/12 es una ley que puede salvar vidas. El proyecto de RCP (Reanimación Cardiopulmonar) se aprobó y se reglamentó en el año 2012. Sin embargo, hoy buscan la modificación del artículo 2 de la norma. Para hablar del tema, el equipo de Cuarto Intermedio dialogó con la senadora Eugenia Catalfamo, legisladora por San Luis, y con el médico Jorge Tartaglione, presidente de la Fundación Cardiológica Argentina y coordinador de la campaña nacional de reanimación cardiovascular. Además, el testimonio de Félix Melo, hermano de Mario Melo, quien falleció durante un concurso de comer medialunas en la costa argentina.

Jorge Tartaglione, médico cardiólogo y presidente de la Fundación Cardiológica Argentina, recoge la historia de doce profesionales que se destacaron durante el siglo pasado y, en Historias de nuestra historia, presenta su nuevo libro "Héroes Argentinos".

Invitado: Dr. Juan Alejandro Vázquez Martínez